Know Cancer

or
forgot password

Duration of Treatment With TKIs in the Treatment of Metastatic Renal Cell Carcinoma


N/A
18 Years
N/A
Open (Enrolling)
Both
Renal Cell Carcinoma

Thank you

Trial Information

Duration of Treatment With TKIs in the Treatment of Metastatic Renal Cell Carcinoma


Inclusion Criteria:



- To be diagnosed as metastatic renal cell carcinoma

- Previous cytokine therapy

- To sign informed consent form (ICF)

Exclusion Criteria:

- Patients not willing to sign informed consent form or who withdraw their consent

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Duration of treatment: from start of tyrosine kinase inhibitor treatment to permanent discontinuation of the product

Outcome Time Frame:

After 2 years

Safety Issue:

No

Principal Investigator

Bayer Study Director

Investigator Role:

Study Director

Investigator Affiliation:

Bayer

Authority:

Turkey: Ministry of Health General Directorate of Pharmaceuticals and Pharmacy

Study ID:

16263

NCT ID:

NCT01585974

Start Date:

November 2012

Completion Date:

December 2014

Related Keywords:

  • Renal Cell Carcinoma
  • Renal Cell Carcinoma
  • TKI
  • Turkey
  • Observational
  • Carcinoma
  • Carcinoma, Renal Cell

Name

Location